Charles River Laboratories International, Inc. Common Stock (CRL)
166.27
+0.70 (0.42%)
Charles River Laboratories International is a global provider of laboratory services that support the pharmaceutical, biotechnology, and medical device industries
The company offers a comprehensive suite of research and development solutions, including essential support for drug discovery, safety assessment, and manufacturing. By providing innovative tools and technologies, as well as expertise in areas such as toxicology and genetic testing, Charles River plays a critical role in advancing biomedical research and helping clients develop and bring new therapies to market efficiently and effectively.
Charles River Laboratories International, Inc. (NYSECRL) will release fourth-quarter and full-year 2024 financial results and provide 2025 guidance on Wednesday, February 19th, before the market opens. A conference call has been scheduled to discuss this information on Wednesday, February 19th, at 8:30 a.m. ET.
Charles River Laboratories International, Inc. (NYSECRL) today announced the launch of Apollo™ for CRADL®, a secure cloud-based platform that enhances leading vivarium rental services through a digital platform that connects clients effortlessly with the training, tools and services needed to start research quickly. As a digital companion to CRADL’s existing rental space offering, Apollo's centralized dashboard seamlessly connects clients to online training, Charles River’s Research Models Online Ordering System, and other study support services.
Charles River Laboratories International, Inc. (NYSECRL) and Akron Bio (“Akron”), a leading supplier of critical materials and services for advanced therapies, today announced the integration of Akron’s Closed System Solutions (CSS)™ line of liquid cytokines produced under current good manufacturing practices (CGMP) onto Charles River’s Cell Therapy Flex Platform for Process Development. The integration of Akron’s line of liquid cytokines further enables closed system processing, which streamlines operations, minimizes risk, and improves process robustness.
Wall Street saw a modest uptick on Tuesday as investors turned their focus to upcoming US inflation data following a better-than-expected producer price index (PPI) report.
Charles River Laboratories International, Inc. (NYSECRL) announced today that it will present at the 43rd Annual J.P. Morgan Healthcare Conference on Tuesday, January 14th, at 2:15 p.m. PT (5:15 p.m. ET). Management will present an overview of Charles River’s strategic focus, business developments, and recent trends.
Charles River Laboratories International, Inc. (NYSECRL) today announced the launch of the Charles River Incubator Program (CIP), specializing in supporting early-stage biotechnology companies in the discovery, development and phase-appropriate manufacturing of advanced therapies.
Charles River Laboratories International, Inc. (NYSECRL) announced today that it will present at the 7th Annual Evercore ISI HealthCONx Conference on Wednesday, December 4th, at 10:00 a.m. ET. Management will provide an overview of Charles River’s strategic focus, business developments, and recent trends.
Charles River Laboratories International, Inc. (NYSECRL) announced today that it will present at the UBS Global Healthcare Conference on Tuesday, November 12th, at 10:15 a.m. PT (1:15 p.m. ET), and the Jefferies London Healthcare Conference on Wednesday, November 20th, at 2:00 p.m. GMT (9:00 a.m. ET).
Charles River Labs Q3 revenue of $1.01 billion surpassed expectations; however, revenue declined 1.6% YoY, and operating margin dropped to 11.6% amid restructuring costs.
Charles River Laboratories International, Inc. (NYSECRL) today reported its results for the third quarter of 2024. For the quarter, revenue was $1.01 billion, a decrease of 1.6% from $1.03 billion in the third quarter of 2023.
Charles River Laboratories International, Inc. (NYSECRL) today announced the launch of the Retrogenix® Non-Human Protein Library. The non-human protein library helps biopharmaceutical clients assess off-target binding to a non-human proteome to de-risk in vivo studies and aid in non-human species selection.
Charles River Laboratories International, Inc. (NYSECRL) will release third-quarter 2024 financial results on Wednesday, November 6th, before the market opens. A conference call has been scheduled to discuss this information on Wednesday, November 6th, at 9:30 a.m. ET.
Charles River Laboratories International, Inc. (NYSECRL) today announced that its team of neuroscience drug discovery experts will present 18 scientific posters, both independently and collaboratively with clients, at Neuroscience 2024, the annual meeting of the Society for Neuroscience (SfN). The meeting, which brings together leading researchers from across the globe, will take place from October 5-9 in Chicago, IL.
Charles River Laboratories International, Inc. (NYSECRL) today announced an agreement with H. Lundbeck A/S (Lundbeck) to utilize Logica® to progress critical brain disease research.
Charles River Laboratories International, Inc. (NYSECRL) and CEBINA GmbH, Central European Biotech Incubator and Accelerator, today announced a strategic collaboration within the acceleration program DanubeNeuro, an initiative focused on identifying and advancing pioneering academic research projects with the potential to create new drugs and innovative technologies in the field of neurodegeneration.
